Blood Processing Devices & Consumables Market by Product Type (Consumables, Devices), Technology (Automated Processing, Manual Processing), Application, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Blood Processing Devices & Consumables Market was valued at USD 51.93 billion in 2024 and is projected to grow to USD 55.25 billion in 2025, with a CAGR of 7.12%, reaching USD 90.05 billion by 2032.
Contextual introduction that frames the essential clinical, technological, and operational foundations shaping blood processing devices and consumables today
The modern healthcare ecosystem depends on reliable, safe, and efficient blood processing devices and consumables to sustain transfusion medicine, diagnostics, and research. These components underpin critical workflows across blood collection, processing, testing, and storage, serving both acute clinical settings and long-term public health programs. Advances in device automation, improvements in consumable sterility and packaging, and stricter pathogen mitigation measures have together elevated the technical and operational expectations for suppliers and end users.
As demand patterns shift, stakeholders must reconcile clinical imperatives with supply chain realities, regulatory scrutiny, and the drive toward cost efficiency. Hospitals, blood banks, and diagnostic laboratories increasingly prioritize throughput, traceability, and quality assurance, while researchers and manufacturers explore novel materials and methods to reduce risk and extend usability. Within this environment, strategic investment, technology adoption, and collaborative supply relationships determine which organizations can respond nimbly to emergent public health needs.
This introduction frames the subsequent analysis by focusing on the intersection of clinical need, technological evolution, and market dynamics. It foregrounds the importance of interoperability, end-user training, and continuous quality improvement as prerequisites for realizing the clinical benefits of new devices and consumables.
Transformative technological, regulatory, and supply chain shifts that are redefining product expectations and competitive dynamics across the blood processing ecosystem
The landscape for blood processing devices and consumables is changing rapidly under the influence of technological breakthroughs, regulatory tightening, and shifting service delivery models. Automation is one of the most consequential shifts: adoption of fully automated and semi-automated processing platforms reduces manual handling, shortens turnaround times, and improves reproducibility, thereby raising expectations for upstream consumable compatibility and downstream data integration.
Concurrently, pathogen reduction systems and advanced diagnostic capabilities are reshaping risk management and clinical decision workflows. These technologies demand new consumable formats and validation pathways, and they force legacy manufacturers to adapt product portfolios. Supply chain resilience has risen to prominence as geopolitical pressures and component shortages highlight single-source vulnerabilities; manufacturers and procurers alike are expanding geographic footprints and qualifying secondary suppliers.
Sustainability and lifecycle thinking are also taking root, influencing design choices for blood bags, filters, and packaging while prompting stakeholders to evaluate total cost of ownership rather than unit price alone. Together, these shifts accelerate consolidation among suppliers, stimulate partnerships between device providers and consumable specialists, and create new opportunities for service-focused business models that bundle equipment, disposables, and analytics.
Assessment of how 2025 tariff shifts are driving strategic regionalization, supplier requalification, and pricing model evolution across blood processing supply chains
Tariff policy changes announced for 2025 have a cumulative ripple effect across the blood processing devices and consumables value chain by altering input costs, sourcing decisions, and pricing strategies. Elevated duties on imported medical components increase landed costs for capital equipment and single-use items, prompting manufacturers to reassess production footprints and to accelerate nearshoring or vertical integration where feasible. These adjustments can improve long-term supply security but require capital investment and revalidation of manufacturing processes to preserve product performance and regulatory compliance.
End users face the practical consequences of these cost shifts through procurement cycles that increasingly emphasize supplier diversification and long-term contracting to stabilize pricing. Payers and health systems may respond by tightening tender specifications or extending contract durations, which in turn pressures vendors to offer bundled services or value-based pricing models that absorb some tariff-related cost fluctuations. Regulatory agencies and trade bodies may also become more active in negotiating exemptions or harmonizing standards to reduce administrative friction associated with cross-border movement of medical goods.
In aggregate, tariffs act as a catalyst for structural change: they intensify the drive toward regional manufacturing clusters, influence decisions about platform standardization versus customization, and strengthen incentives for innovation that reduces dependence on tariff-exposed inputs. Strategic planning must therefore account for not only immediate cost impacts but also longer-term shifts in supplier ecosystems and investment priorities.
Comprehensive segmentation analysis demonstrating how product, technology, application, end user, and channel dimensions interact to define diverse buyer needs and supplier strategies
Insightful segmentation reveals how distinct product, technology, application, end user, and distribution dimensions interact to shape demand and competitive strategy. Based on product type, the market divides into consumables and devices, where consumables encompass anticoagulants and additives, blood bags and sets, filters, and test kits while devices include apheresis machines, centrifuges, pathogen reduction systems, and storage equipment. This product split highlights divergent innovation cycles: consumables emphasize cost, sterility, and regulatory traceability, whereas devices prioritize automation, uptime, and integration with laboratory information systems.
Based on technology, processing approaches are separated into automated processing and manual processing, with automated processing further categorized into fully automated systems and semi automated systems. This technological segmentation signals a migration toward platforms that reduce operator dependency while requiring compatible consumables and enhanced service offerings. Based on application, demand maps to blood collection, component separation, diagnostic testing, pathogen reduction, and storage and transportation, each of which imposes specific performance and regulatory requirements.
Based on end user, adoption patterns differ across blood banks, diagnostic laboratories, hospitals and clinics, and research institutes, reflecting varied purchasing cycles, volume needs, and technical capabilities. Based on distribution channel, procurement flows through direct sales, distributors, and e-commerce, with channel choice influencing lead times, aftersales support, and pricing transparency. Appreciating how these segments overlap helps suppliers tailor product design, commercialization tactics, and service delivery to distinct buyer personas and operational constraints.
Regional dynamics and adoption patterns across the Americas, Europe Middle East and Africa, and Asia Pacific that determine regulatory strategy and commercial prioritization
Regional dynamics exert a powerful influence on technology adoption, regulatory pathways, and supply chain architectures. In the Americas, a combination of advanced clinical infrastructure and concentrated procurement budgets accelerates uptake of automated platforms and pathogen reduction technologies, while mature regulatory frameworks demand extensive clinical validation and quality systems. Conversely, fragmented procurement networks and cost sensitivity in many jurisdictions require suppliers to offer flexible financing and modular solutions that can scale across facility tiers.
In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variability in hospital capabilities and payer models, encouraging regional distributor partnerships and adaptable service models. Manufacturers often maintain multiple approval pathways and localized manufacturing or warehousing to meet diverse compliance regimes and to minimize cross-border delays. In the Asia-Pacific region, rapid expansion of diagnostic capacity, growing domestic manufacturing bases, and investments in cold chain infrastructure are catalyzing demand for both high-throughput devices and cost-effective consumables, though market entry requires careful navigation of heterogeneous regulatory and reimbursement landscapes.
These regional contrasts influence where companies prioritize R&D, clinical trials, and commercial investments, and they underscore the importance of aligning go-to-market tactics with local procurement practices, logistics realities, and end-user training needs.
Strategic company archetypes and competitive behaviors that reveal how established players, specialized manufacturers, and innovators are shaping market evolution
Market participants span multinational medical technology firms, specialized consumables manufacturers, diagnostic companies, contract manufacturers, and niche innovators focused on pathogen reduction or automation. Established equipment providers derive competitive advantage from broad installed bases, service networks, and integrated software ecosystems, enabling them to offer bundled solutions that combine devices, consumables, and analytics. Meanwhile, specialized consumables makers are pursuing incremental material and process improvements to reduce failure rates, extend shelf life, and meet sustainability objectives.
Newer entrants and technology-focused startups concentrate on developing disruptive subsystems-such as compact pathogen reduction modules or single-use automation cartridges-that can be licensed or partnered into larger platforms. Contract manufacturers and regional OEMs play a strategic role by offering scalable production capacity and rapid time-to-market for validated designs, which is particularly valuable when tariffs or logistics require geographically diversified output. Across these company types, successful firms are those that balance product innovation with robust quality systems, flexible commercial models, and proactive regulatory engagement to shorten adoption cycles and build long-term customer trust.
Practical and high-impact recommendations for manufacturers, suppliers, and purchasers to strengthen resilience, accelerate adoption, and optimize long-term value delivery
Industry leaders should adopt a multi-pronged approach that balances supply security, technology investment, and customer-centric commercial models. First, diversify manufacturing and component sourcing to reduce exposure to geopolitical and tariff-related disruptions, while investing in local validation and quality assurance to speed regulatory approvals in target regions. Second, accelerate selective automation initiatives and modular device designs that lower total cost of ownership and improve compatibility with evolving laboratory information systems.
Third, reconfigure commercial offerings toward outcome-based and bundled services that combine equipment, consumables, maintenance, and data analytics to deepen customer relationships and create recurring revenue streams. Fourth, prioritize sustainability by redesigning packaging and consumables for lower environmental impact and by communicating lifecycle benefits to procurement teams seeking long-term value. Fifth, strengthen partnerships with distributors and local service providers to ensure rapid installation, training, and aftermarket support, particularly in regions with limited in-house technical capacity.
Finally, invest in proactive regulatory engagement and clinical evidence generation to shorten adoption lead times, and leverage targeted M&A or licensing where specialized technologies can accelerate roadmap objectives. These measures together position organizations to capture opportunities while mitigating systemic risk.
Transparent and rigorous research methodology combining expert interviews, regulatory review, and data triangulation to ensure credible insights and practical relevance
The research underpinning this report integrates multiple evidence streams and validation steps to ensure robustness and practical relevance. Primary qualitative inputs include structured interviews with procurement leaders, laboratory directors, clinical end users, and manufacturing executives, which illuminate operational pain points, adoption barriers, and unmet needs. Secondary research encompassed public regulatory documents, clinical guidance, device registries, and peer-reviewed literature to contextualize technological performance and safety considerations.
Data triangulation was applied by cross-referencing supplier product literature with independently reported clinical studies and feedback from end users to identify consistent trends versus anecdotal observations. Where possible, manufacturing and logistics assessments were corroborated through site visits and third-party audits to verify resilience claims. Key limitations include variability in regional reporting standards and a lag between emerging innovations and their broader clinical adoption; these were mitigated by weighting current validated deployments more heavily than prototype-stage concepts.
Analytical methods used scenario analysis to explore tariff impacts and sensitivity testing to examine how changes in automation adoption or supply chain disruptions would influence procurement strategies. Outputs were peer-reviewed by subject matter experts to ensure that conclusions are practical, actionable, and aligned with frontline clinical priorities.
Concluding synthesis that emphasizes resilience, evidence-based adoption, and strategic partnerships as the core drivers of sustained competitive advantage
The convergence of automation, pathogen mitigation, and supply chain realignment is reshaping priorities across the blood processing ecosystem. Organizations that align product portfolios to the distinct needs of consumables versus devices, that invest in validated automation pathways, and that pursue diversified manufacturing footprints will be better positioned to navigate tariff-driven cost pressures and regional regulatory complexities. End users will continue to demand solutions that offer measurable improvements in safety, throughput, and traceability, which incentivizes vendors to offer integrated hardware, consumables, and digital services.
In light of these dynamics, strategic focus should center on building resilient partnerships, accelerating evidence generation for clinical benefit, and designing commercial models that absorb variability in procurement cycles. The sector’s evolution underscores that incremental product improvements matter, but systemic changes-such as service bundling, regional manufacturing, and rigorous postmarket surveillance-will determine which players achieve sustainable leadership. Ultimately, the organizations that combine operational excellence with customer-centric innovation will capture the most enduring value as the landscape continues to evolve.
Note: PDF & Excel + Online Access - 1 Year
Contextual introduction that frames the essential clinical, technological, and operational foundations shaping blood processing devices and consumables today
The modern healthcare ecosystem depends on reliable, safe, and efficient blood processing devices and consumables to sustain transfusion medicine, diagnostics, and research. These components underpin critical workflows across blood collection, processing, testing, and storage, serving both acute clinical settings and long-term public health programs. Advances in device automation, improvements in consumable sterility and packaging, and stricter pathogen mitigation measures have together elevated the technical and operational expectations for suppliers and end users.
As demand patterns shift, stakeholders must reconcile clinical imperatives with supply chain realities, regulatory scrutiny, and the drive toward cost efficiency. Hospitals, blood banks, and diagnostic laboratories increasingly prioritize throughput, traceability, and quality assurance, while researchers and manufacturers explore novel materials and methods to reduce risk and extend usability. Within this environment, strategic investment, technology adoption, and collaborative supply relationships determine which organizations can respond nimbly to emergent public health needs.
This introduction frames the subsequent analysis by focusing on the intersection of clinical need, technological evolution, and market dynamics. It foregrounds the importance of interoperability, end-user training, and continuous quality improvement as prerequisites for realizing the clinical benefits of new devices and consumables.
Transformative technological, regulatory, and supply chain shifts that are redefining product expectations and competitive dynamics across the blood processing ecosystem
The landscape for blood processing devices and consumables is changing rapidly under the influence of technological breakthroughs, regulatory tightening, and shifting service delivery models. Automation is one of the most consequential shifts: adoption of fully automated and semi-automated processing platforms reduces manual handling, shortens turnaround times, and improves reproducibility, thereby raising expectations for upstream consumable compatibility and downstream data integration.
Concurrently, pathogen reduction systems and advanced diagnostic capabilities are reshaping risk management and clinical decision workflows. These technologies demand new consumable formats and validation pathways, and they force legacy manufacturers to adapt product portfolios. Supply chain resilience has risen to prominence as geopolitical pressures and component shortages highlight single-source vulnerabilities; manufacturers and procurers alike are expanding geographic footprints and qualifying secondary suppliers.
Sustainability and lifecycle thinking are also taking root, influencing design choices for blood bags, filters, and packaging while prompting stakeholders to evaluate total cost of ownership rather than unit price alone. Together, these shifts accelerate consolidation among suppliers, stimulate partnerships between device providers and consumable specialists, and create new opportunities for service-focused business models that bundle equipment, disposables, and analytics.
Assessment of how 2025 tariff shifts are driving strategic regionalization, supplier requalification, and pricing model evolution across blood processing supply chains
Tariff policy changes announced for 2025 have a cumulative ripple effect across the blood processing devices and consumables value chain by altering input costs, sourcing decisions, and pricing strategies. Elevated duties on imported medical components increase landed costs for capital equipment and single-use items, prompting manufacturers to reassess production footprints and to accelerate nearshoring or vertical integration where feasible. These adjustments can improve long-term supply security but require capital investment and revalidation of manufacturing processes to preserve product performance and regulatory compliance.
End users face the practical consequences of these cost shifts through procurement cycles that increasingly emphasize supplier diversification and long-term contracting to stabilize pricing. Payers and health systems may respond by tightening tender specifications or extending contract durations, which in turn pressures vendors to offer bundled services or value-based pricing models that absorb some tariff-related cost fluctuations. Regulatory agencies and trade bodies may also become more active in negotiating exemptions or harmonizing standards to reduce administrative friction associated with cross-border movement of medical goods.
In aggregate, tariffs act as a catalyst for structural change: they intensify the drive toward regional manufacturing clusters, influence decisions about platform standardization versus customization, and strengthen incentives for innovation that reduces dependence on tariff-exposed inputs. Strategic planning must therefore account for not only immediate cost impacts but also longer-term shifts in supplier ecosystems and investment priorities.
Comprehensive segmentation analysis demonstrating how product, technology, application, end user, and channel dimensions interact to define diverse buyer needs and supplier strategies
Insightful segmentation reveals how distinct product, technology, application, end user, and distribution dimensions interact to shape demand and competitive strategy. Based on product type, the market divides into consumables and devices, where consumables encompass anticoagulants and additives, blood bags and sets, filters, and test kits while devices include apheresis machines, centrifuges, pathogen reduction systems, and storage equipment. This product split highlights divergent innovation cycles: consumables emphasize cost, sterility, and regulatory traceability, whereas devices prioritize automation, uptime, and integration with laboratory information systems.
Based on technology, processing approaches are separated into automated processing and manual processing, with automated processing further categorized into fully automated systems and semi automated systems. This technological segmentation signals a migration toward platforms that reduce operator dependency while requiring compatible consumables and enhanced service offerings. Based on application, demand maps to blood collection, component separation, diagnostic testing, pathogen reduction, and storage and transportation, each of which imposes specific performance and regulatory requirements.
Based on end user, adoption patterns differ across blood banks, diagnostic laboratories, hospitals and clinics, and research institutes, reflecting varied purchasing cycles, volume needs, and technical capabilities. Based on distribution channel, procurement flows through direct sales, distributors, and e-commerce, with channel choice influencing lead times, aftersales support, and pricing transparency. Appreciating how these segments overlap helps suppliers tailor product design, commercialization tactics, and service delivery to distinct buyer personas and operational constraints.
Regional dynamics and adoption patterns across the Americas, Europe Middle East and Africa, and Asia Pacific that determine regulatory strategy and commercial prioritization
Regional dynamics exert a powerful influence on technology adoption, regulatory pathways, and supply chain architectures. In the Americas, a combination of advanced clinical infrastructure and concentrated procurement budgets accelerates uptake of automated platforms and pathogen reduction technologies, while mature regulatory frameworks demand extensive clinical validation and quality systems. Conversely, fragmented procurement networks and cost sensitivity in many jurisdictions require suppliers to offer flexible financing and modular solutions that can scale across facility tiers.
In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variability in hospital capabilities and payer models, encouraging regional distributor partnerships and adaptable service models. Manufacturers often maintain multiple approval pathways and localized manufacturing or warehousing to meet diverse compliance regimes and to minimize cross-border delays. In the Asia-Pacific region, rapid expansion of diagnostic capacity, growing domestic manufacturing bases, and investments in cold chain infrastructure are catalyzing demand for both high-throughput devices and cost-effective consumables, though market entry requires careful navigation of heterogeneous regulatory and reimbursement landscapes.
These regional contrasts influence where companies prioritize R&D, clinical trials, and commercial investments, and they underscore the importance of aligning go-to-market tactics with local procurement practices, logistics realities, and end-user training needs.
Strategic company archetypes and competitive behaviors that reveal how established players, specialized manufacturers, and innovators are shaping market evolution
Market participants span multinational medical technology firms, specialized consumables manufacturers, diagnostic companies, contract manufacturers, and niche innovators focused on pathogen reduction or automation. Established equipment providers derive competitive advantage from broad installed bases, service networks, and integrated software ecosystems, enabling them to offer bundled solutions that combine devices, consumables, and analytics. Meanwhile, specialized consumables makers are pursuing incremental material and process improvements to reduce failure rates, extend shelf life, and meet sustainability objectives.
Newer entrants and technology-focused startups concentrate on developing disruptive subsystems-such as compact pathogen reduction modules or single-use automation cartridges-that can be licensed or partnered into larger platforms. Contract manufacturers and regional OEMs play a strategic role by offering scalable production capacity and rapid time-to-market for validated designs, which is particularly valuable when tariffs or logistics require geographically diversified output. Across these company types, successful firms are those that balance product innovation with robust quality systems, flexible commercial models, and proactive regulatory engagement to shorten adoption cycles and build long-term customer trust.
Practical and high-impact recommendations for manufacturers, suppliers, and purchasers to strengthen resilience, accelerate adoption, and optimize long-term value delivery
Industry leaders should adopt a multi-pronged approach that balances supply security, technology investment, and customer-centric commercial models. First, diversify manufacturing and component sourcing to reduce exposure to geopolitical and tariff-related disruptions, while investing in local validation and quality assurance to speed regulatory approvals in target regions. Second, accelerate selective automation initiatives and modular device designs that lower total cost of ownership and improve compatibility with evolving laboratory information systems.
Third, reconfigure commercial offerings toward outcome-based and bundled services that combine equipment, consumables, maintenance, and data analytics to deepen customer relationships and create recurring revenue streams. Fourth, prioritize sustainability by redesigning packaging and consumables for lower environmental impact and by communicating lifecycle benefits to procurement teams seeking long-term value. Fifth, strengthen partnerships with distributors and local service providers to ensure rapid installation, training, and aftermarket support, particularly in regions with limited in-house technical capacity.
Finally, invest in proactive regulatory engagement and clinical evidence generation to shorten adoption lead times, and leverage targeted M&A or licensing where specialized technologies can accelerate roadmap objectives. These measures together position organizations to capture opportunities while mitigating systemic risk.
Transparent and rigorous research methodology combining expert interviews, regulatory review, and data triangulation to ensure credible insights and practical relevance
The research underpinning this report integrates multiple evidence streams and validation steps to ensure robustness and practical relevance. Primary qualitative inputs include structured interviews with procurement leaders, laboratory directors, clinical end users, and manufacturing executives, which illuminate operational pain points, adoption barriers, and unmet needs. Secondary research encompassed public regulatory documents, clinical guidance, device registries, and peer-reviewed literature to contextualize technological performance and safety considerations.
Data triangulation was applied by cross-referencing supplier product literature with independently reported clinical studies and feedback from end users to identify consistent trends versus anecdotal observations. Where possible, manufacturing and logistics assessments were corroborated through site visits and third-party audits to verify resilience claims. Key limitations include variability in regional reporting standards and a lag between emerging innovations and their broader clinical adoption; these were mitigated by weighting current validated deployments more heavily than prototype-stage concepts.
Analytical methods used scenario analysis to explore tariff impacts and sensitivity testing to examine how changes in automation adoption or supply chain disruptions would influence procurement strategies. Outputs were peer-reviewed by subject matter experts to ensure that conclusions are practical, actionable, and aligned with frontline clinical priorities.
Concluding synthesis that emphasizes resilience, evidence-based adoption, and strategic partnerships as the core drivers of sustained competitive advantage
The convergence of automation, pathogen mitigation, and supply chain realignment is reshaping priorities across the blood processing ecosystem. Organizations that align product portfolios to the distinct needs of consumables versus devices, that invest in validated automation pathways, and that pursue diversified manufacturing footprints will be better positioned to navigate tariff-driven cost pressures and regional regulatory complexities. End users will continue to demand solutions that offer measurable improvements in safety, throughput, and traceability, which incentivizes vendors to offer integrated hardware, consumables, and digital services.
In light of these dynamics, strategic focus should center on building resilient partnerships, accelerating evidence generation for clinical benefit, and designing commercial models that absorb variability in procurement cycles. The sector’s evolution underscores that incremental product improvements matter, but systemic changes-such as service bundling, regional manufacturing, and rigorous postmarket surveillance-will determine which players achieve sustainable leadership. Ultimately, the organizations that combine operational excellence with customer-centric innovation will capture the most enduring value as the landscape continues to evolve.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of pathogen reduction technologies for platelet and plasma safety
- 5.2. Integration of artificial intelligence and predictive analytics in blood processing workflows
- 5.3. Development of closed-system blood collection and processing kits to minimize contamination risk
- 5.4. Surge in advanced apheresis systems offering high-throughput multi-component collection capabilities
- 5.5. Growth in single-use consumables for plasma fractionation to enhance scalability and reduce cross-contamination
- 5.6. Expansion of mobile and point-of-care blood separation units for remote and emergency settings
- 5.7. Emergence of universal blood processing platforms compatible with multiple anticoagulants and anticoagulant-free methods
- 5.8. Regulatory emphasis on standardized safety protocols driving adoption of automated blood centrifugation devices
- 5.9. Rising investment in microfluidic-based diagnostics for rapid on-site blood component analysis and quality assurance
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Blood Processing Devices & Consumables Market, by Product Type
- 8.1. Consumables
- 8.1.1. Anticoagulants And Additives
- 8.1.2. Blood Bags And Sets
- 8.1.3. Filters
- 8.1.4. Test Kits
- 8.2. Devices
- 8.2.1. Apheresis Machines
- 8.2.2. Centrifuges
- 8.2.3. Pathogen Reduction Systems
- 8.2.4. Storage Equipment
- 9. Blood Processing Devices & Consumables Market, by Technology
- 9.1. Automated Processing
- 9.1.1. Fully Automated Systems
- 9.1.2. Semi Automated Systems
- 9.2. Manual Processing
- 10. Blood Processing Devices & Consumables Market, by Application
- 10.1. Blood Collection
- 10.2. Component Separation
- 10.3. Diagnostic Testing
- 10.4. Pathogen Reduction
- 10.5. Storage And Transportation
- 11. Blood Processing Devices & Consumables Market, by End User
- 11.1. Blood Banks
- 11.2. Diagnostic Laboratories
- 11.3. Hospitals And Clinics
- 11.4. Research Institutes
- 12. Blood Processing Devices & Consumables Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Distributors
- 12.3. E Commerce
- 13. Blood Processing Devices & Consumables Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Blood Processing Devices & Consumables Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Blood Processing Devices & Consumables Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Terumo Corporation
- 16.3.2. Haemonetics Corporation
- 16.3.3. Grifols, S.A.
- 16.3.4. Abbott Laboratories
- 16.3.5. Becton, Dickinson and Company
- 16.3.6. Fresenius Kabi
- 16.3.7. Bio-Rad Laboratories, Inc.
- 16.3.8. Macopharma SA
- 16.3.9. F. Hoffmann-La Roche Ltd.
- 16.3.10. Danaher Corporation
- 16.3.11. Immucor, Inc.
- 16.3.12. Thermo Fisher Scientific Inc.
- 16.3.13. Baxter International
- 16.3.14. bioMérieux SA
- 16.3.15. ThermoGenesis Holdings, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
